The National Comprehensive Cancer Network provides a list of preferred primary therapy regimens for transplant-eligible and nontransplant candidates and lists drugs recommended for maintenance therapy ...
MM survival rates have improved with the introduction of novel agents. Treatment of MM within the first year is associated with improved survival. New research has concluded that, despite more ...
Using nationwide electronic health record (EHR) and cancer registry data from the VA Corporate Data Warehouse, we developed and validated a rule-based NLP algorithm to extract oncologist-determined MM ...
Patients taking ACE inhibitors and ARBs saw a 16% reduction in their risk of cancer progression (HR, 0.84; 95% CI, 0.71-0.99; ...
Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer ASCO Guidelines provide ...
Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...
2025 MAY 26 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily-- New research on Oncology - Multiple Myeloma is the subject of a report. According to news ...
All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results